Grifols (GRFS) Current Leases (2016 - 2023)
Grifols (GRFS) reported Current Leases of $115.2 million for Q4 2023, up 10.35% on a YoY basis from $104.4 million in Q4 2022, and up 10.35% quarter-over-quarter from $104.4 million in Q4 2022.
Grifols (GRFS) Current Leases (2016 - 2023) Analysis & Trends
Grifols has reported Current Leases for 8 years, with the latest figure at $115.2 million in Q4 2023.
- For the quarter ending Q4 2023, Current Leases rose 10.35% year-over-year to $115.2 million; the trailing twelve-month figure through Dec 2023 stood at $115.2 million (up 10.35% YoY), and the FY2023 full-year result was $115.2 million, up 10.35% from the prior year.
- Current Leases for Q4 2023 stood at $115.2 million, up from $104.4 million in the prior quarter.
- The five-year high for Current Leases was $115.2 million in Q4 2023, with the low at $49.2 million in Q4 2019.
- Historically, Current Leases has averaged $75.0 million across 5 years, with a median of $55.6 million in 2021.
- Annual changes were most pronounced in 2019 — Current Leases soared 1186.21% — and 2020, when it grew 3.44%.
- Grifols' Current Leases stood at $49.2 million in 2019, then rose by 3.44% to $50.8 million in 2020, then advanced by 9.28% to $55.6 million in 2021, then soared by 87.96% to $104.4 million in 2022, then gained by 10.35% to $115.2 million in 2023.
- The last three Current Leases figures came in at $115.2 million (Q4 2023), $104.4 million (Q4 2022), and $55.6 million (Q4 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 115.23 Mn |
| Dec 31, 2022 | 104.43 Mn |
| Dec 31, 2021 | 55.56 Mn |
| Dec 31, 2020 | 50.84 Mn |
| Dec 31, 2019 | 49.15 Mn |
| Dec 31, 2018 | 3.82 Mn |
| Dec 31, 2017 | 4.64 Mn |
| Dec 31, 2016 | 4.17 Mn |